Imatinib-resistance without BCR/ABL Point Mutation in Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) is a myeloproliferative bone marrow neoplasm that occurs because of a fusion gene called BCR-ABL1. Imatinib -the inhibitor of this fusion geneis the target therapy in CML. But unfortunately, resistance against imatinib occurs in some patients. In September 2019 47-year...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2024-03-01
|
| Series: | Caucasian Medical Journal |
| Subjects: | |
| Online Access: | https://caucasianmedj.com/articles/imatinib-resistance-without-bcrabl-point-mutation-in-chronic-myeloid-leukemia/doi/cmj.galenos.2024.36855 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|